Alnylam Pharmaceuticals
ALNY
#601
Rank
A$52.15 B
Marketcap
$404.37
Share price
4.37%
Change (1 day)
43.43%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -A$0.28 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$2.09 Billion. In 2023 the company made an earning of -A$0.51 Billion, an increase over its 2022 earnings that were of -A$1.57 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$0.28 Billion-45.55%
2023 -A$0.51 Billion-67.84%
2022 -A$1.57 Billion36.93%
2021 -A$1.15 Billion-8.04%
2020 -A$1.25 Billion-15.66%
2019 -A$1.48 Billion12.23%
2018 -A$1.32 Billion62.91%
2017 -A$0.81 Billion17.78%
2016 -A$0.69 Billion43.44%
2015 -A$0.48 Billion60.69%
2014 -A$0.3 Billion98.2%
2013 -A$0.15 Billion
2011 -A$88.31 Million27.48%
2010 -A$69.28 Million-10.92%
2009 -A$77.77 Million95.77%
2008 -A$39.73 Million
2006 -A$63.64 Million-9.13%
2005 -A$70.04 Million34.74%
2004 -A$51.98 Million36.79%
2003 -A$38 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$0.94 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
A$8.00 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.20 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.19 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$66.65 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
A$20.51 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$11.93 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
A$0.67 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel